Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 8330

Next Previous
X
Search
Drug Profile

AZD 8330

Alternative Names: ARRY-424704; ARRY-704; AZD8330

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma
  • Developer AstraZeneca
  • Class Amides; Aniline compounds; Antineoplastics; Dihydropyridines; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 30 Jul 2019 Array Biopharma has been acquired by Pfizer
  • 30 Jun 2013 Discontinued - Phase-I for Solid tumours in USA and Norway (PO)
  • 31 Mar 2011 AstraZeneca completes its phase I trial for Solid tumours in USA and Norway (NCT00454090)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top